Cancer during pregnancy is relatively rare but is increasing in frequency in countries in
which the maternal child-bearing age continues to rise. The complexities of medical decision …

The role of neoadjuvant therapy (NAT) for localized breast cancer has evolved tremendously
over the past several years. Currently, NAT is the preferred option for high-risk early triple …

Due to the lack of definitive hormone receptors, triple negative breast cancer (TNBC)
patients receive little clinical benefit from endocrine or molecular targeted therapies, leading …

Objectives We performed a systematic review and meta-analysis to evaluate the impact of
18 F-FDG PET, PET/CT, and PET/MRI on staging and management during the initial staging …

Chemotherapy is an essential treatment for breast cancer, inducing cancer cell death.
However, chemoresistance is a problem that limits the effectiveness of chemotherapy. Many …

Importance Given the widespread use of the 21-gene recurrence score for identifying
candidates for adjuvant chemotherapy, it is important to examine the performance of the …

Current follow-up policies for early breast cancer aim to detect loco-regional recurrences
and manage treatment-related adverse effects. Their “one size fits all” approach does not …

Triple-negative breast cancer (TNBC) has a high rate of metastasis, which is associated with
breast cancer stem-like cells (CSCs). Although Taxol (micelle formulation of paclitaxel) is the …

Gene expression-based recurrence assays are strongly recommended to guide the use of
chemotherapy in hormone receptor-positive, HER2-negative breast cancer, but such testing …

In recent years, the incidence of breast cancer has been increasing on an annual basis.
Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human …